Smithkline Beecham Corporation

Glaxosmithkline LLC

Anacor Pharmaceuticals, Inc.

Katherine L Widdowson

Hong Nie

Melvin Clarence Rutledge, Jr

Anthony Joseph Jurewicz

Daniel F Veber

Qi Jin

Michael R Palovich

Robert Philip Hertzberg

John G Gleason

James Francis Callahan

Jeffrey Charles Boehm

Dashyant Dhanak

Xichen Lin

Jeffrey K Kerns

Jakob Busch-Petersen

Sonia M Thomas

Melvin C Rutledge

Michael Lindenmuth

Jianghe Deng

Brent W McCleland

Deborah Lynn Bryan

Joseph Weinstock

Steven David Knight

Scott Kevin Thompson

Zehong Wan

Ralph F Hall

Roderick Alan Porter

Richard McCulloch Keenan

Michael Richard Kevin Alley

Amanda Johns

Christopher E Neipp

John Richard White

Stacie Marie Halbert

Guoliang Lin

Jian Jin

James Brackley, Iii

Gregory Lee Warren

Wei Fu

Huijie Li

Yonghui Wang

Hongyi Yu

George Chan

Gregory L Adams

Jack J Taggart

Robert Phillip Hertzberg

Feng Wang

Guangping Bi

Michelle Werner

Michael Robert Palovich

Norvaline and/or other amino acids that are capable of being acylated onto tRNAby LeuRS, in combination with substituted benzoxaboroles, such as a compound having a structure according to formula III: and methods for decreasing the frequency of resistance and/or reducing the rate of resistance and/or suppressing the emergence of resistance that develops in bacteria exposed to a substituted benzoxaborole or salt thereof by administering a combination of a substituted benzoxaborole such as a compound of formula III or salt thereof and an amino acid or a salt thereof.

Benzoxaborole compounds and uses thereof

The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK&#x3b2;) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Chemical compounds

This invention relates to novel compounds, compositions and combinations thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

IL-8 receptor antagonists

This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

Compounds

Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.

This invention relates to the novel use of dianilino squarates in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Il-8 receptor antagonists

This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

This invention relates to the novel use of diphenyl sulfamido in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

The invention relates to the use of guanidine compounds in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Growing community of inventors

King of Prussia, PA, United States of America

Katherine L Widdowson